UroGen Pharma Ltd.
StreetZero Signal 54
About UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible reverse thermal gelation hydrogel technology, along with products such as Zusduri for non-muscle invasive bladder cancer. The company is publicly traded on Nasdaq under URGN and maintains operations in Ra'anana, Israel, and Princeton, New Jersey, with 300 employees.
LATEST FUNDINGRule 144
$90K
Announced 2026-10-09
TOTAL RAISED$7M
IN THE NEWS
- 🔗 UroGen Pharma - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants | UroGen Pharma, Ltd
- 🔗 What You Need To Know About UroGen Pharma Ltd.'s (NASDAQ:URGN) Investor Composition
- 🔗 UroGen Pharma Ltd
- 🔗 UroGen Pharma Ltd Stock Price Today | NASDAQ: URGN Live - Investing.com
EMPLOYEES251-500
FOUNDED2004
HQRa'anana, Israel
Industry
Public Equity (Nasdaq)
Tags
BiotechPublicCancer TherapeuticsUrology
Investors
Key highlights
- Total funding of $7M across 4 rounds with 14 institutional investors.
- Publicly listed on Nasdaq as URGN with market cap around $339M.
- Recently priced public offering of ordinary shares and pre-funded warrants.
- Developer of RTGel technology for sustained drug release in cancer treatment.
- Focus on urothelial and specialty cancers with commercial products like Zusduri.
Ask StreetZero about UroGen Pharma Ltd.
Put our AI to work on this deal.
Similar companies
Other Public Equity (Nasdaq) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account